Oral Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation (Tablets, Capsules, Drops, Liquid or Syrup), By Type (Controlled Release, Orodispersible Tablets, Others), By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others), By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others), By Region and Competition, 2019-2029F
Global Oral Drug Delivery Market was valued at USD 120.44 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.74% through 2029.The Oral Drug Delivery Market encompasses the sector within the pharmaceutical industry dedicated to the development, manufacturing, and commercialization of medications administered via the oral route. This market segment is of paramount importance as oral drug delivery is one of the most common and preferred methods for medication administration due to its convenience, ease of use, and patient compliance. Oral drug delivery systems encompass a wide range of formulations, including tablets, capsules, liquids, and orally disintegrating tablets, among others. Within this market, pharmaceutical companies invest heavily in research and development to innovate new drug delivery technologies aimed at enhancing drug efficacy, bioavailability, and patient outcomes.
Key Market Drivers
Rising Prevalence of Chronic Diseases
The escalating prevalence of chronic diseases worldwide, comprising ailments such as cardiovascular diseases, diabetes, and cancer, stands as a formidable driver propelling the growth trajectory of the Global Oral Drug Delivery Market. This surge in chronic conditions poses a significant healthcare challenge, necessitating effective management and treatment strategies. As the burden of chronic diseases continues to mount, there emerges an ever-growing demand for oral medications that provide not only therapeutic efficacy but also convenience and long-term management options for patients. Oral drug delivery systems offer a crucial solution by providing a non-invasive and easily administrable route for medication intake. This convenience factor plays a pivotal role in enhancing patient adherence to prescribed treatment regimens, a critical aspect in achieving optimal therapeutic outcomes. By simplifying the medication process and minimizing discomfort associated with other routes of drug administration, oral drug delivery systems effectively empower patients to adhere to their treatment plans diligently. Consequently, this enhanced patient compliance not only fosters better disease management but also drives the sustained growth and expansion of the Global Oral Drug Delivery Market, as pharmaceutical companies continue to invest in innovative formulations and technologies to meet the evolving needs of patients worldwide.
Technological Innovations in Drug Delivery Platforms
Technological innovations in drug delivery platforms are playing a pivotal role in shaping the evolution of the Global Oral Drug Delivery Market. With relentless advancements, novel delivery systems such as oral films, implants, and buccal patches have emerged as frontrunners, offering a paradigm shift in drug administration strategies. These cutting-edge technologies not only facilitate traditional drug delivery but also offer distinctive advantages such as targeted delivery, controlled release, and site-specific action, thus revolutionizing the treatment landscape.
Oral films, for instance, represent a groundbreaking innovation in drug delivery, providing a thin, flexible, and dissolvable platform for drug administration. These films can be conveniently placed on the tongue or inside the cheek, facilitating rapid drug absorption and bypassing the digestive system for enhanced bioavailability. Similarly, implants offer a sustained-release mechanism, releasing medication gradually over an extended period, thereby reducing dosing frequency and enhancing patient compliance. Additionally, buccal patches provide localized delivery of drugs through the mucous membrane of the cheek, enabling targeted therapy and minimizing systemic side effects.
Expanding Pharmaceutical Industry Investments
The Global Oral Drug Delivery Market derives substantial benefits from the considerable investments poured into research, development, and commercialization of oral drug delivery technologies by pharmaceutical companies. These investments serve as catalysts propelling innovation within the market, fostering the rapid introduction of novel oral formulations, and nurturing collaborative endeavors among industry stakeholders, thus fueling overall market growth.
Pharmaceutical companies' robust investments in research and development represent a cornerstone of progress within the Global Oral Drug Delivery Market. These investments fuel the exploration of cutting-edge technologies, formulation techniques, and delivery systems aimed at enhancing drug efficacy, improving patient compliance, and mitigating adverse effects. By allocating resources towards innovative research initiatives, pharmaceutical firms drive the development of next-generation oral drug delivery technologies, thereby expanding the market's scope and potential.Moreover, the commercialization of oral drug delivery technologies is accelerated by substantial investments from pharmaceutical companies. These investments fund pivotal clinical trials, regulatory approvals, and market launches, facilitating the swift transition of promising drug delivery innovations from laboratory to pharmacy shelves. As pharmaceutical companies commit significant financial resources to commercialization efforts, they expedite the availability of new oral formulations to healthcare providers and patients worldwide, thereby stimulating market growth.
Government Initiatives to Improve Healthcare Access
Government initiatives aimed at enhancing healthcare access and affordability play a pivotal role in bolstering the growth of the global oral drug delivery market. These initiatives encompass a spectrum of policies and programs geared towards fostering an environment conducive to market expansion, driving demand for oral medications, and promoting improved patient outcomes.
One significant aspect of government initiatives is the promotion of generic drug utilization through policies aimed at increasing affordability and accessibility of medications. By encouraging the use of generic equivalents of branded drugs, governments can lower healthcare costs for patients and healthcare systems alike, thereby expanding access to oral medications. This increased accessibility fosters market growth by broadening the patient base and driving demand for oral drug delivery products.
Government interventions in drug pricing regulations contribute to the growth of the Global Oral Drug Delivery Market. Price regulations aimed at controlling the cost of pharmaceuticals help ensure affordability for patients and healthcare systems, thereby stimulating demand for oral medications. By implementing policies that balance affordability with pharmaceutical innovation, governments create a stable market environment conducive to sustained growth and expansion.
Key Market Challenges
Bioavailability Enhancement
One of the foremost challenges facing the Global Oral Drug Delivery Market is enhancing the bioavailability of orally administered medications. Many drugs encounter significant degradation and poor absorption in the gastrointestinal tract, leading to reduced efficacy and therapeutic outcomes. Overcoming these barriers requires innovative formulation approaches, such as the use of nanotechnology, lipid-based formulations, and novel excipients, to improve drug solubility, permeability, and stability. Additionally, optimizing drug release profiles and absorption kinetics through controlled-release formulations and drug delivery systems represents a critical area of focus for pharmaceutical companies seeking to maximize the therapeutic potential of oral medications.
Regulatory Compliance and Intellectual Property Protection
Regulatory compliance and intellectual property protection present significant challenges for companies operating in the Global Oral Drug Delivery Market. Developing innovative oral drug delivery technologies necessitates navigating complex regulatory frameworks to ensure compliance with safety, efficacy, and quality standards set forth by regulatory authorities worldwide. Additionally, protecting intellectual property rights is essential for safeguarding investments in research and development and maintaining a competitive edge in the market. Effective strategies for navigating regulatory requirements and securing intellectual property rights are essential for sustaining innovation and driving growth in the Global Oral Drug Delivery Market.
Key Market Trends
Personalized Medicine and Customized Formulations
One notable trend shaping the Global Oral Drug Delivery Market is the shift towards personalized medicine and customized formulations. As advancements in biotechnology and pharmacogenomics continue to unfold, there is an increasing recognition of the importance of tailoring drug therapies to individual patient characteristics such as genetic makeup, disease profile, and lifestyle factors. This trend is driving the development of innovative oral drug delivery systems capable of delivering precise dosages and formulations tailored to meet the unique needs of each patient. Pharmaceutical companies are investing in technologies such as 3D printing and nanotechnology to enable the production of personalized oral drug formulations, thereby enhancing treatment efficacy and patient outcomes.
Integration of Digital Health Technologies
Another significant trend in the Global Oral Drug Delivery Market is the integration of digital health technologies into oral drug delivery systems. With the proliferation of smartphones, wearables, and connected devices, there is a growing opportunity to enhance medication adherence, monitoring, and patient engagement through digital solutions. Pharmaceutical companies are increasingly incorporating features such as smart pill bottles, medication reminder apps, and real-time tracking sensors into oral drug delivery devices to empower patients and healthcare providers with actionable insights into medication adherence and treatment response. This trend not only improves patient outcomes but also facilitates data-driven decision-making and clinical research in the field of oral drug delivery.
Segmental Insights
Formulation Insights
Based on the Formulation, in the global Oral Drug Delivery Market, tablets stand out as the dominant formulation method. Tablets have secured their prominence due to several compelling factors. Tablets offer unparalleled convenience and ease of administration, making them a preferred choice for patients across diverse demographics. Their solid form allows for convenient storage, transport, and dosing accuracy, enhancing patient compliance and medication adherence.
Additionally, tablets facilitate precise dosing and formulation control, enabling pharmaceutical companies to deliver a wide range of active pharmaceutical ingredients (APIs) in a stable and reproducible manner. Furthermore, tablets can be manufactured using a variety of technologies, including immediate-release, modified-release, and extended-release formulations, catering to diverse therapeutic needs and patient preferences. Moreover, tablets often undergo rigorous quality control measures and stability testing, ensuring their efficacy, safety, and shelf-life. Overall, tablets' versatility, convenience, and reliability position them as the dominant formulation method in the global Oral Drug Delivery Market, driving their widespread adoption and market dominance.
Type Insights
Based on the Type segment, the Controlled Release type stands out as the dominant type among the various categories. This dominance can be attributed to several key factors. Controlled release formulations offer significant advantages over conventional immediate-release formulations by providing sustained and controlled drug release over an extended period. This allows for less frequent dosing, improved patient compliance, and enhanced therapeutic efficacy.
As a result, pharmaceutical companies are increasingly investing in the development of controlled release oral drug delivery systems across a wide range of therapeutic areas, including chronic diseases such as diabetes, hypertension, and pain management. Moreover, advancements in drug delivery technologies, such as matrix systems, osmotic pumps, and microencapsulation techniques, have enabled the precise modulation of drug release kinetics, further enhancing the therapeutic benefits of controlled release formulations.
Additionally, the growing prevalence of chronic diseases worldwide, coupled with an aging population and increasing healthcare expenditure, drives the demand for long-acting oral medications that offer sustained symptom relief and improved disease management. Consequently, the controlled release segment continues to dominate the global Oral Drug Delivery Market, offering significant growth opportunities for pharmaceutical companies and driving advancements in drug delivery science and technology.
Regional Insights
North America emerges as the dominant region in the Global Oral Drug Delivery Market. Several factors contribute to its prominence in this market segment. North America boasts a robust pharmaceutical industry with a high level of research and development investment, leading to continuous innovation in oral drug delivery technologies. The region benefits from advanced healthcare infrastructure and a well-established regulatory framework that facilitates the development, approval, and commercialization of oral drug delivery products.
A significant portion of pharmaceutical companies specializing in oral drug delivery systems are headquartered in North America, further bolstering its leadership position. Moreover, the region has a large patient population with a high prevalence of chronic diseases, driving the demand for oral medications and propelling market growth. Favorable reimbursement policies and strong market competition contribute to the dynamic and thriving nature of the oral drug delivery market in North America.
Key Market Players
Novartis AG
Biocon Ltd.
NovoNordisk A/S
F.Hoffmann-La Roche Ltd.
Bayer AG
Emishphere Technologies Inc.
Enteris Biopharma Inc.
Merrion Pharmaceuticals Plc.
Amgen Inc.
Pfizer Inc.
Report Scope:
In this report, the Global Oral Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oral Drug Delivery Market, By Formulation:
oTablets
oCapsules
oDrops
oLiquid or Syrup
Oral Drug Delivery Market, By Type:
oControlled Release
oOrodispersible Tablets
oOthers
Oral Drug Delivery Market, By Therapy Area:
oOncology
oMusculoskeletal
oImmunology
oGastrointestinal
oRespiratory
oCardiovascular
oOthers
Oral Drug Delivery Market, By End User:
oHospitals
oAmbulatory Surgical Centres
oDiagnostic Centres
oClinics
oOthers
Oral Drug Delivery Market, By Region:
oNorth America
Company Profiles: Detailed analysis of the major companies present in the Global Oral Drug Delivery Market.
Available Customizations:
Global Oral Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Key Market Drivers
Rising Prevalence of Chronic Diseases
The escalating prevalence of chronic diseases worldwide, comprising ailments such as cardiovascular diseases, diabetes, and cancer, stands as a formidable driver propelling the growth trajectory of the Global Oral Drug Delivery Market. This surge in chronic conditions poses a significant healthcare challenge, necessitating effective management and treatment strategies. As the burden of chronic diseases continues to mount, there emerges an ever-growing demand for oral medications that provide not only therapeutic efficacy but also convenience and long-term management options for patients. Oral drug delivery systems offer a crucial solution by providing a non-invasive and easily administrable route for medication intake. This convenience factor plays a pivotal role in enhancing patient adherence to prescribed treatment regimens, a critical aspect in achieving optimal therapeutic outcomes. By simplifying the medication process and minimizing discomfort associated with other routes of drug administration, oral drug delivery systems effectively empower patients to adhere to their treatment plans diligently. Consequently, this enhanced patient compliance not only fosters better disease management but also drives the sustained growth and expansion of the Global Oral Drug Delivery Market, as pharmaceutical companies continue to invest in innovative formulations and technologies to meet the evolving needs of patients worldwide.
Technological Innovations in Drug Delivery Platforms
Technological innovations in drug delivery platforms are playing a pivotal role in shaping the evolution of the Global Oral Drug Delivery Market. With relentless advancements, novel delivery systems such as oral films, implants, and buccal patches have emerged as frontrunners, offering a paradigm shift in drug administration strategies. These cutting-edge technologies not only facilitate traditional drug delivery but also offer distinctive advantages such as targeted delivery, controlled release, and site-specific action, thus revolutionizing the treatment landscape.
Oral films, for instance, represent a groundbreaking innovation in drug delivery, providing a thin, flexible, and dissolvable platform for drug administration. These films can be conveniently placed on the tongue or inside the cheek, facilitating rapid drug absorption and bypassing the digestive system for enhanced bioavailability. Similarly, implants offer a sustained-release mechanism, releasing medication gradually over an extended period, thereby reducing dosing frequency and enhancing patient compliance. Additionally, buccal patches provide localized delivery of drugs through the mucous membrane of the cheek, enabling targeted therapy and minimizing systemic side effects.
Expanding Pharmaceutical Industry Investments
The Global Oral Drug Delivery Market derives substantial benefits from the considerable investments poured into research, development, and commercialization of oral drug delivery technologies by pharmaceutical companies. These investments serve as catalysts propelling innovation within the market, fostering the rapid introduction of novel oral formulations, and nurturing collaborative endeavors among industry stakeholders, thus fueling overall market growth.
Pharmaceutical companies' robust investments in research and development represent a cornerstone of progress within the Global Oral Drug Delivery Market. These investments fuel the exploration of cutting-edge technologies, formulation techniques, and delivery systems aimed at enhancing drug efficacy, improving patient compliance, and mitigating adverse effects. By allocating resources towards innovative research initiatives, pharmaceutical firms drive the development of next-generation oral drug delivery technologies, thereby expanding the market's scope and potential.Moreover, the commercialization of oral drug delivery technologies is accelerated by substantial investments from pharmaceutical companies. These investments fund pivotal clinical trials, regulatory approvals, and market launches, facilitating the swift transition of promising drug delivery innovations from laboratory to pharmacy shelves. As pharmaceutical companies commit significant financial resources to commercialization efforts, they expedite the availability of new oral formulations to healthcare providers and patients worldwide, thereby stimulating market growth.
Government Initiatives to Improve Healthcare Access
Government initiatives aimed at enhancing healthcare access and affordability play a pivotal role in bolstering the growth of the global oral drug delivery market. These initiatives encompass a spectrum of policies and programs geared towards fostering an environment conducive to market expansion, driving demand for oral medications, and promoting improved patient outcomes.
One significant aspect of government initiatives is the promotion of generic drug utilization through policies aimed at increasing affordability and accessibility of medications. By encouraging the use of generic equivalents of branded drugs, governments can lower healthcare costs for patients and healthcare systems alike, thereby expanding access to oral medications. This increased accessibility fosters market growth by broadening the patient base and driving demand for oral drug delivery products.
Government interventions in drug pricing regulations contribute to the growth of the Global Oral Drug Delivery Market. Price regulations aimed at controlling the cost of pharmaceuticals help ensure affordability for patients and healthcare systems, thereby stimulating demand for oral medications. By implementing policies that balance affordability with pharmaceutical innovation, governments create a stable market environment conducive to sustained growth and expansion.
Key Market Challenges
Bioavailability Enhancement
One of the foremost challenges facing the Global Oral Drug Delivery Market is enhancing the bioavailability of orally administered medications. Many drugs encounter significant degradation and poor absorption in the gastrointestinal tract, leading to reduced efficacy and therapeutic outcomes. Overcoming these barriers requires innovative formulation approaches, such as the use of nanotechnology, lipid-based formulations, and novel excipients, to improve drug solubility, permeability, and stability. Additionally, optimizing drug release profiles and absorption kinetics through controlled-release formulations and drug delivery systems represents a critical area of focus for pharmaceutical companies seeking to maximize the therapeutic potential of oral medications.
Regulatory Compliance and Intellectual Property Protection
Regulatory compliance and intellectual property protection present significant challenges for companies operating in the Global Oral Drug Delivery Market. Developing innovative oral drug delivery technologies necessitates navigating complex regulatory frameworks to ensure compliance with safety, efficacy, and quality standards set forth by regulatory authorities worldwide. Additionally, protecting intellectual property rights is essential for safeguarding investments in research and development and maintaining a competitive edge in the market. Effective strategies for navigating regulatory requirements and securing intellectual property rights are essential for sustaining innovation and driving growth in the Global Oral Drug Delivery Market.
Key Market Trends
Personalized Medicine and Customized Formulations
One notable trend shaping the Global Oral Drug Delivery Market is the shift towards personalized medicine and customized formulations. As advancements in biotechnology and pharmacogenomics continue to unfold, there is an increasing recognition of the importance of tailoring drug therapies to individual patient characteristics such as genetic makeup, disease profile, and lifestyle factors. This trend is driving the development of innovative oral drug delivery systems capable of delivering precise dosages and formulations tailored to meet the unique needs of each patient. Pharmaceutical companies are investing in technologies such as 3D printing and nanotechnology to enable the production of personalized oral drug formulations, thereby enhancing treatment efficacy and patient outcomes.
Integration of Digital Health Technologies
Another significant trend in the Global Oral Drug Delivery Market is the integration of digital health technologies into oral drug delivery systems. With the proliferation of smartphones, wearables, and connected devices, there is a growing opportunity to enhance medication adherence, monitoring, and patient engagement through digital solutions. Pharmaceutical companies are increasingly incorporating features such as smart pill bottles, medication reminder apps, and real-time tracking sensors into oral drug delivery devices to empower patients and healthcare providers with actionable insights into medication adherence and treatment response. This trend not only improves patient outcomes but also facilitates data-driven decision-making and clinical research in the field of oral drug delivery.
Segmental Insights
Formulation Insights
Based on the Formulation, in the global Oral Drug Delivery Market, tablets stand out as the dominant formulation method. Tablets have secured their prominence due to several compelling factors. Tablets offer unparalleled convenience and ease of administration, making them a preferred choice for patients across diverse demographics. Their solid form allows for convenient storage, transport, and dosing accuracy, enhancing patient compliance and medication adherence.
Additionally, tablets facilitate precise dosing and formulation control, enabling pharmaceutical companies to deliver a wide range of active pharmaceutical ingredients (APIs) in a stable and reproducible manner. Furthermore, tablets can be manufactured using a variety of technologies, including immediate-release, modified-release, and extended-release formulations, catering to diverse therapeutic needs and patient preferences. Moreover, tablets often undergo rigorous quality control measures and stability testing, ensuring their efficacy, safety, and shelf-life. Overall, tablets' versatility, convenience, and reliability position them as the dominant formulation method in the global Oral Drug Delivery Market, driving their widespread adoption and market dominance.
Type Insights
Based on the Type segment, the Controlled Release type stands out as the dominant type among the various categories. This dominance can be attributed to several key factors. Controlled release formulations offer significant advantages over conventional immediate-release formulations by providing sustained and controlled drug release over an extended period. This allows for less frequent dosing, improved patient compliance, and enhanced therapeutic efficacy.
As a result, pharmaceutical companies are increasingly investing in the development of controlled release oral drug delivery systems across a wide range of therapeutic areas, including chronic diseases such as diabetes, hypertension, and pain management. Moreover, advancements in drug delivery technologies, such as matrix systems, osmotic pumps, and microencapsulation techniques, have enabled the precise modulation of drug release kinetics, further enhancing the therapeutic benefits of controlled release formulations.
Additionally, the growing prevalence of chronic diseases worldwide, coupled with an aging population and increasing healthcare expenditure, drives the demand for long-acting oral medications that offer sustained symptom relief and improved disease management. Consequently, the controlled release segment continues to dominate the global Oral Drug Delivery Market, offering significant growth opportunities for pharmaceutical companies and driving advancements in drug delivery science and technology.
Regional Insights
North America emerges as the dominant region in the Global Oral Drug Delivery Market. Several factors contribute to its prominence in this market segment. North America boasts a robust pharmaceutical industry with a high level of research and development investment, leading to continuous innovation in oral drug delivery technologies. The region benefits from advanced healthcare infrastructure and a well-established regulatory framework that facilitates the development, approval, and commercialization of oral drug delivery products.
A significant portion of pharmaceutical companies specializing in oral drug delivery systems are headquartered in North America, further bolstering its leadership position. Moreover, the region has a large patient population with a high prevalence of chronic diseases, driving the demand for oral medications and propelling market growth. Favorable reimbursement policies and strong market competition contribute to the dynamic and thriving nature of the oral drug delivery market in North America.
Key Market Players
Novartis AG
Biocon Ltd.
NovoNordisk A/S
F.Hoffmann-La Roche Ltd.
Bayer AG
Emishphere Technologies Inc.
Enteris Biopharma Inc.
Merrion Pharmaceuticals Plc.
Amgen Inc.
Pfizer Inc.
Report Scope:
In this report, the Global Oral Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oral Drug Delivery Market, By Formulation:
oTablets
oCapsules
oDrops
oLiquid or Syrup
Oral Drug Delivery Market, By Type:
oControlled Release
oOrodispersible Tablets
oOthers
Oral Drug Delivery Market, By Therapy Area:
oOncology
oMusculoskeletal
oImmunology
oGastrointestinal
oRespiratory
oCardiovascular
oOthers
Oral Drug Delivery Market, By End User:
oHospitals
oAmbulatory Surgical Centres
oDiagnostic Centres
oClinics
oOthers
Oral Drug Delivery Market, By Region:
oNorth America
- United States
- Canada
- Mexico
- France
- United Kingdom
- Italy
- Germany
- Spain
- China
- India
- Japan
- Australia
- South Korea
- Brazil
- Argentina
- Colombia
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Oral Drug Delivery Market.
Available Customizations:
Global Oral Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
1.PRODUCT OVERVIEW
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.RESEARCH METHODOLOGY
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.EXECUTIVE SUMMARY
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market
4.VOICE OF CUSTOMER
5.GLOBAL ORAL DRUG DELIVERY MARKET OUTLOOK
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
5.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
5.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
5.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
5.2.5.By Company (2023)
5.2.6.By Region
5.3.Market Map
6.NORTH AMERICA ORAL DRUG DELIVERY MARKET OUTLOOK
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
6.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
6.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
6.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
6.2.5.By Country
6.3.North America: Country Analysis
6.3.1.United States Oral Drug Delivery Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Formulation
6.3.1.2.2.By Type
6.3.1.2.3.By Therapy Area
6.3.1.2.4.By End User
6.3.2.Canada Oral Drug Delivery Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Formulation
6.3.2.2.2.By Type
6.3.2.2.3.By Therapy Area
6.3.2.2.4.By End User
6.3.3.Mexico Oral Drug Delivery Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Formulation
6.3.3.2.2.By Type
6.3.3.2.3.By Therapy Area
6.3.3.2.4.By End User
7.EUROPE ORAL DRUG DELIVERY MARKET OUTLOOK
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
7.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
7.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
7.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
7.2.5.By Country
7.3.Europe: Country Analysis
7.3.1.France Oral Drug Delivery Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Formulation
7.3.1.2.2.By Type
7.3.1.2.3.By Therapy Area
7.3.1.2.4.By End User
7.3.2.Germany Oral Drug Delivery Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Formulation
7.3.2.2.2.By Type
7.3.2.2.3.By Therapy Area
7.3.2.2.4.By End User
7.3.3.United Kingdom Oral Drug Delivery Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.By Formulation
7.3.3.2.2.By Type
7.3.3.2.3.By Therapy Area
7.3.3.2.4.By End User
7.3.4.Italy Oral Drug Delivery Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Formulation
7.3.4.2.2.By Type
7.3.4.2.3.By Therapy Area
7.3.4.2.4.By End User
7.3.5.Spain Oral Drug Delivery Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Formulation
7.3.5.2.2.By Type
7.3.5.2.3.By Therapy Area
7.3.5.2.4.By End User
8.ASIA-PACIFIC ORAL DRUG DELIVERY MARKET OUTLOOK
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
8.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
8.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
8.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
8.2.5.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Oral Drug Delivery Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Formulation
8.3.1.2.2.By Type
8.3.1.2.3.By Therapy Area
8.3.1.2.4.By End User
8.3.2.India Oral Drug Delivery Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Formulation
8.3.2.2.2.By Type
8.3.2.2.3.By Therapy Area
8.3.2.2.4.By End User
8.3.3.Japan Oral Drug Delivery Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Formulation
8.3.3.2.2.By Type
8.3.3.2.3.By Therapy Area
8.3.3.2.4.By End User
8.3.4.South Korea Oral Drug Delivery Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Formulation
8.3.4.2.2.By Type
8.3.4.2.3.By Therapy Area
8.3.4.2.4.By End User
8.3.5.Australia Oral Drug Delivery Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Formulation
8.3.5.2.2.By Type
8.3.5.2.3.By Therapy Area
8.3.5.2.4.By End User
9.SOUTH AMERICA ORAL DRUG DELIVERY MARKET OUTLOOK
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
9.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
9.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
9.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
9.2.5.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Oral Drug Delivery Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Formulation
9.3.1.2.2.By Type
9.3.1.2.3.By Therapy Area
9.3.1.2.4.By End User
9.3.2.Argentina Oral Drug Delivery Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Formulation
9.3.2.2.2.By Type
9.3.2.2.3.By Therapy Area
9.3.2.2.4.By End User
9.3.3.Colombia Oral Drug Delivery Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Formulation
9.3.3.2.2.By Type
9.3.3.2.3.By Therapy Area
9.3.3.2.4.By End User
10.MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY MARKET OUTLOOK
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
10.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
10.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
10.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
10.2.5.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Oral Drug Delivery Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Formulation
10.3.1.2.2.By Type
10.3.1.2.3.By Therapy Area
10.3.1.2.4.By End User
10.3.2.Saudi Arabia Oral Drug Delivery Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Formulation
10.3.2.2.2.By Type
10.3.2.2.3.By Therapy Area
10.3.2.2.4.By End User
10.3.3.UAE Oral Drug Delivery Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Formulation
10.3.3.2.2.By Type
10.3.3.2.3.By Therapy Area
10.3.3.2.4.By End User
11.MARKET DYNAMICS
11.1.Drivers
11.2.Challenges
12.MARKET TRENDS DEVELOPMENTS
12.1.Merger Acquisition (If Any)
12.2.Product Launches (If Any)
12.3.Recent Developments
13.PORTERS FIVE FORCES ANALYSIS
13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Products
14.COMPETITIVE LANDSCAPE
14.1.Novartis AG
14.1.1.Business Overview
14.1.2.Company Snapshot
14.1.3.Products Services
14.1.4.Financials (As Reported)
14.1.5.Recent Developments
14.1.6.Key Personnel Details
14.1.7.SWOT Analysis
14.2.Biocon Ltd.
14.3.NovoNordisk A/S
14.4.F.Hoffmann-La Roche Ltd.
14.5.Bayer AG
14.6.Emishphere Technologies Inc.
14.7.Enteris Biopharma Inc.
14.8.Merrion Pharmaceuticals Plc.
14.9.Amgen Inc.
14.10.Pfizer Inc.
15.STRATEGIC RECOMMENDATIONS
16.ABOUT US DISCLAIMER
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.RESEARCH METHODOLOGY
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.EXECUTIVE SUMMARY
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market
4.VOICE OF CUSTOMER
5.GLOBAL ORAL DRUG DELIVERY MARKET OUTLOOK
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
5.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
5.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
5.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
5.2.5.By Company (2023)
5.2.6.By Region
5.3.Market Map
6.NORTH AMERICA ORAL DRUG DELIVERY MARKET OUTLOOK
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
6.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
6.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
6.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
6.2.5.By Country
6.3.North America: Country Analysis
6.3.1.United States Oral Drug Delivery Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Formulation
6.3.1.2.2.By Type
6.3.1.2.3.By Therapy Area
6.3.1.2.4.By End User
6.3.2.Canada Oral Drug Delivery Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Formulation
6.3.2.2.2.By Type
6.3.2.2.3.By Therapy Area
6.3.2.2.4.By End User
6.3.3.Mexico Oral Drug Delivery Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Formulation
6.3.3.2.2.By Type
6.3.3.2.3.By Therapy Area
6.3.3.2.4.By End User
7.EUROPE ORAL DRUG DELIVERY MARKET OUTLOOK
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
7.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
7.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
7.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
7.2.5.By Country
7.3.Europe: Country Analysis
7.3.1.France Oral Drug Delivery Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Formulation
7.3.1.2.2.By Type
7.3.1.2.3.By Therapy Area
7.3.1.2.4.By End User
7.3.2.Germany Oral Drug Delivery Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Formulation
7.3.2.2.2.By Type
7.3.2.2.3.By Therapy Area
7.3.2.2.4.By End User
7.3.3.United Kingdom Oral Drug Delivery Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.By Formulation
7.3.3.2.2.By Type
7.3.3.2.3.By Therapy Area
7.3.3.2.4.By End User
7.3.4.Italy Oral Drug Delivery Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Formulation
7.3.4.2.2.By Type
7.3.4.2.3.By Therapy Area
7.3.4.2.4.By End User
7.3.5.Spain Oral Drug Delivery Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Formulation
7.3.5.2.2.By Type
7.3.5.2.3.By Therapy Area
7.3.5.2.4.By End User
8.ASIA-PACIFIC ORAL DRUG DELIVERY MARKET OUTLOOK
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
8.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
8.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
8.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
8.2.5.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Oral Drug Delivery Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Formulation
8.3.1.2.2.By Type
8.3.1.2.3.By Therapy Area
8.3.1.2.4.By End User
8.3.2.India Oral Drug Delivery Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Formulation
8.3.2.2.2.By Type
8.3.2.2.3.By Therapy Area
8.3.2.2.4.By End User
8.3.3.Japan Oral Drug Delivery Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Formulation
8.3.3.2.2.By Type
8.3.3.2.3.By Therapy Area
8.3.3.2.4.By End User
8.3.4.South Korea Oral Drug Delivery Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Formulation
8.3.4.2.2.By Type
8.3.4.2.3.By Therapy Area
8.3.4.2.4.By End User
8.3.5.Australia Oral Drug Delivery Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Formulation
8.3.5.2.2.By Type
8.3.5.2.3.By Therapy Area
8.3.5.2.4.By End User
9.SOUTH AMERICA ORAL DRUG DELIVERY MARKET OUTLOOK
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
9.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
9.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
9.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
9.2.5.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Oral Drug Delivery Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Formulation
9.3.1.2.2.By Type
9.3.1.2.3.By Therapy Area
9.3.1.2.4.By End User
9.3.2.Argentina Oral Drug Delivery Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Formulation
9.3.2.2.2.By Type
9.3.2.2.3.By Therapy Area
9.3.2.2.4.By End User
9.3.3.Colombia Oral Drug Delivery Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Formulation
9.3.3.2.2.By Type
9.3.3.2.3.By Therapy Area
9.3.3.2.4.By End User
10.MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY MARKET OUTLOOK
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
10.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
10.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
10.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
10.2.5.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Oral Drug Delivery Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Formulation
10.3.1.2.2.By Type
10.3.1.2.3.By Therapy Area
10.3.1.2.4.By End User
10.3.2.Saudi Arabia Oral Drug Delivery Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Formulation
10.3.2.2.2.By Type
10.3.2.2.3.By Therapy Area
10.3.2.2.4.By End User
10.3.3.UAE Oral Drug Delivery Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Formulation
10.3.3.2.2.By Type
10.3.3.2.3.By Therapy Area
10.3.3.2.4.By End User
11.MARKET DYNAMICS
11.1.Drivers
11.2.Challenges
12.MARKET TRENDS DEVELOPMENTS
12.1.Merger Acquisition (If Any)
12.2.Product Launches (If Any)
12.3.Recent Developments
13.PORTERS FIVE FORCES ANALYSIS
13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Products
14.COMPETITIVE LANDSCAPE
14.1.Novartis AG
14.1.1.Business Overview
14.1.2.Company Snapshot
14.1.3.Products Services
14.1.4.Financials (As Reported)
14.1.5.Recent Developments
14.1.6.Key Personnel Details
14.1.7.SWOT Analysis
14.2.Biocon Ltd.
14.3.NovoNordisk A/S
14.4.F.Hoffmann-La Roche Ltd.
14.5.Bayer AG
14.6.Emishphere Technologies Inc.
14.7.Enteris Biopharma Inc.
14.8.Merrion Pharmaceuticals Plc.
14.9.Amgen Inc.
14.10.Pfizer Inc.
15.STRATEGIC RECOMMENDATIONS
16.ABOUT US DISCLAIMER
